102 related articles for article (PubMed ID: 7606199)
1. Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial.
Pendyala L; Creaven PJ
Cancer Epidemiol Biomarkers Prev; 1995; 4(3):245-51. PubMed ID: 7606199
[TBL] [Abstract][Full Text] [Related]
2. Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity.
Pendyala L; Schwartz G; Bolanowska-Higdon W; Hitt S; Zdanowicz J; Murphy M; Lawrence D; Creaven PJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):269-72. PubMed ID: 11303598
[TBL] [Abstract][Full Text] [Related]
3. Distribution of radio-labeled N-Acetyl-L-Cysteine in Sprague-Dawley rats and its effect on glutathione metabolism following single and repeat dosing by oral gavage.
Arfsten DP; Johnson EW; Wilfong ER; Jung AE; Bobb AJ
Cutan Ocul Toxicol; 2007; 26(2):113-34. PubMed ID: 17612979
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans.
Creaven PJ; Pendyala L; Petrelli NJ
Cancer Epidemiol Biomarkers Prev; 1993; 2(3):243-7. PubMed ID: 8318877
[TBL] [Abstract][Full Text] [Related]
5. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
6. Impact of 30-day oral dosing with N-acetyl-L-cysteine on Sprague-Dawley rat physiology.
Arfsten D; Johnson E; Thitoff A; Jung A; Wilfong E; Lohrke S; Bausman T; Eggers J; Bobb A
Int J Toxicol; 2004; 23(4):239-47. PubMed ID: 15371168
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
Marshall JL; Wellstein A; Rae J; DeLap RJ; Phipps K; Hanfelt J; Yunmbam MK; Sun JX; Duchin KL; Hawkins MJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2347-54. PubMed ID: 9815633
[TBL] [Abstract][Full Text] [Related]
8. Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients.
Benson AB; Olopade OI; Ratain MJ; Rademaker A; Mobarhan S; Stucky-Marshall L; French S; Dolan ME
Clin Cancer Res; 2000 Oct; 6(10):3870-7. PubMed ID: 11051232
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Ryan QC; Headlee D; Acharya M; Sparreboom A; Trepel JB; Ye J; Figg WD; Hwang K; Chung EJ; Murgo A; Melillo G; Elsayed Y; Monga M; Kalnitskiy M; Zwiebel J; Sausville EA
J Clin Oncol; 2005 Jun; 23(17):3912-22. PubMed ID: 15851766
[TBL] [Abstract][Full Text] [Related]
13. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
16. Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine.
de Quay B; Malinverni R; Lauterburg BH
AIDS; 1992 Aug; 6(8):815-9. PubMed ID: 1418777
[TBL] [Abstract][Full Text] [Related]
17. Increase in glucose consumption by acetylcysteine during hyperglycemic clamp. A study with healthy volunteers.
Ammon HP; Müller PH; Eggstein M; Wintermantel C; Aigner B; Safayhi H; Stützle M; Renn W
Arzneimittelforschung; 1992 May; 42(5):642-5. PubMed ID: 1530678
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Muggia FM; Wu X; Spicer D; Groshen S; Jeffers S; Leichman CG; Leichman L; Chan KK
Clin Cancer Res; 1996 Sep; 2(9):1461-7. PubMed ID: 9816321
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
20. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
